The time courses of onset of the electrophysiologic and antiarrhythmic effects of amiodarone were determined with serial electrophysiologic studies in 34 patients with inducible ventricular tachycardia. A standardized oral loading dosage was used for all patients (1,200 mg/day for 14 days; 800 mg/day for 7 days; and 400 mg/day thereafter). Eleven patients had the studies performed at baseline and after 2, 6, 10, and 20 weeks. Subsequently, 23 patients had studies at baseline and after 2 and 10 weeks. Changes in atrial, sinus, and atrioventricular nodal properties and in conduction intervals were maximal within 2 weeks (early effects). For example, atrioventricular nodal Wenckebach cycle length increased between baseline (369±80 msec) and 2 weeks (498± 78 msec) (p<0.001) but did not change further after 10 weeks (500± 89 msec). However, ventricular Class III effects required 10 weeks to become maximal (late effects). For example, the QT interval during atrial pacing increased between baseline (355±36 msec) and 2 weeks (406±37 msec) (p<0.001) and increased further after 10 weeks (436±45 msec) (p<0.001). Antiarrhythmic effects also followed different time courses of onset. Suppression of ventricular premature beats was maximal within 2 weeks. However, suppression of ventricular tachycardia inducibility and slowing of ventricular tachycardia rate was not maximal for 10 weeks. Correlations between serum desethylamiodarone concentrations and some late effects suggest that the mechanism of the time delay to maximal ventricular Class HI effects may involve desethylamiodarone. In conclusion, the time courses of onset of the electrophysiologic and antiarrhythmic effects of amiodarone are dependent on the site and type of effect. (Circulation 1989;80:34-42) Amiodarone was first introduced as an antiarrhythmic agent 20 years ago."2 Since that time, it has been recognized as very effective therapy for a broad spectrum of tachyarrhythmias.3-31 However, widespread acceptance of this agent has been slowed by the potential severity of its many adverse effects6 '8"12"17'28'29,32- use to circumstances where the need for effective therapy outweighs the potential risks. Thus, amiodarone therapy is usually reserved for patients with drug-resistant, life-threatening tachyarrhythmias. The unusual pharmacokinetic features of amiodarone include a very long elimination halflife (approximately 25-60 days),35-38 an active metabolite39-41 that may have an even longer elimination half-life,36'42 and a long time delay between therapy initiation and maximum pharmacologic effects. 7,21,24,25,30 3143-47 These characteristics have resulted in the routine use of loading regimens9'45'48 to shorten the time delay between therapy initiation and maximal effects.
days; 800 mg/day for 7 days; and 400 mg/day thereafter). Eleven patients had the studies performed at baseline and after 2, 6, 10, and 20 weeks. Subsequently, 23 patients had studies at baseline and after 2 and 10 weeks. Changes in atrial, sinus, and atrioventricular nodal properties and in conduction intervals were maximal within 2 weeks (early effects). For example, atrioventricular nodal Wenckebach cycle length increased between baseline (369±80 msec) and 2 weeks (498± 78 msec) (p<0.001) but did not change further after 10 weeks (500± 89 msec). However, ventricular Class III effects required 10 weeks to become maximal (late effects). For example, the QT interval during atrial pacing increased between baseline (355±36 msec) and 2 weeks (406±37 msec) (p<0.001) and increased further after 10 weeks (436±45 msec) (p<0.001). Antiarrhythmic effects also followed different time courses of onset. Suppression of ventricular premature beats was maximal within 2 weeks. However, suppression of ventricular tachycardia inducibility and slowing of ventricular tachycardia rate was not maximal for 10 weeks. Correlations between serum desethylamiodarone concentrations and some late effects suggest that the mechanism of the time delay to maximal ventricular Class HI effects may involve desethylamiodarone. In conclusion, the time courses of onset of the electrophysiologic and antiarrhythmic effects of amiodarone are dependent on the site and type of effect. (Circulation 1989; 80:34-42) Amiodarone was first introduced as an antiarrhythmic agent 20 years ago."2 Since that time, it has been recognized as very effective therapy for a broad spectrum of tachyarrhythmias.3-31 However, widespread acceptance of this agent has been slowed by the potential severity of its many adverse effects6'8"12"17'28 '29,32-34 and by its unusual pharmacokinetics. 35 3 The adverse effect profile of amiodarone has limited its use to circumstances where the need for effective therapy outweighs the potential risks. Thus, amiodarone therapy is usually reserved for patients with drug-resistant, life-threatening tachyarrhythmias. The unusual pharmacokinetic features of amiodarone include a very long elimination halflife (approximately 25-60 days),35-38 an active metabolite39-41 that may have an even longer elimination half-life,36'42 and a long time delay between therapy initiation and maximum pharmacologic effects. 7,21,24,25,30 3143-47 These characteristics have resulted in the routine use of loading regimens9 '45'48 to shorten the time delay between therapy initiation and maximal effects.
The purpose of the present study was to examine the pharmacology of amiodarone therapy initiation with serial studies of patients with symptomatic ventricular tachycardia or ventricular fibrillation. We evaluated specific questions: How long after therapy initiation do the electrophysiologic effects of amiodarone become maximal? Are the time delays 7 days. Thereafter, the daily maintenance dosage was 400 mg. To examine in detail the onset of the electrophysiologic and antiarrhythmic effects of amiodarone, the first 11 patients completing the protocol (group 1) had serum amiodarone and desethylamiodarone concentration determinations, a 24-hour ambulatory electrocardiogram (ECG), and an electrophysiologic study performed at baseline and after 2, 6, 10, and 20 weeks of amiodarone therapy. The data from group 1 patients identified the optimal timing of follow-up studies and indicated that the remaining aims of the study could be achieved by repeating these measurements at less-frequent intervals. Accordingly, the remaining 23 patients completing the protocol (group 2) had these investigations performed at baseline and after 2 and 10 weeks of amiodarone therapy.
The present study was approved by the Conjoint Medical Ethics Committee of the University of Calgary and Foothills Provincial General Hospital.
Electrophysiologic Studies
Electrophysiologic studies were performed with dilute (0.33%) lidocaine local anesthesia. Surface ECG leads I, aVF, and V, were recorded simultaneously with intracardiac electrograms from the high right atrium, His bundle recording site, and right ventricular apex at a paper speed of 100 mm/sec (Electronics for Medicine VR 16, Seimens Mingograf). Cardiac pacing was performed with a programmable stimulator (Bloom Associates) with stimuli 2 msec in duration and of tenfold diastolic threshold intensity.
Electrophysiologic intervals were determined from the mean of five successive cycles during both sinus rhythm and constant rate atrial pacing using standard definitions. 49 The maximum corrected sinus node recovery time (CSNRT) was the longest recovery cycle length minus the spontaneous sinus cycle length observed after 30 seconds of atrial pacing at cycle lengths of 700, 600, 500, and 400 msec. The atrioventricular (AV) node Wenckebach cycle length (WCL) was the cycle length that first conducted with Type I second-degree AV block during decremental atrial pacing. The atrial effective refractory period (AERP), atrial functional refractory period (AFRP), AV 
Results

Study Patients
Forty-one consecutive consenting patients were enrolled in this study. The first 11 patients to complete the protocol had serum drug determinations, ambulatory ECG recordings, and electrophysiologic studies performed at baseline and after 2, 6, 10, and 20 weeks of amiodarone therapy (group 1). The next 23 patients completing the protocol had these investigations performed at baseline and after 2 and 10 weeks of amiodarone therapy (group 2). There were no significant differences in clinical characteristics between group 1 and group 2 patients ( Table 1) . The remaining seven patients did not complete the protocol-one patient died suddenly after 3 weeks of amiodarone therapy, one patient developed unstable angina precluding follow-up electrophysiologic testing, and five patients withdrew consent. Patients who were unable to complete the protocol had a lower mean left ventricular ejection fraction (0.26+0.12) than patients who completed the protocol (0.38+0.14) (p=0.04), but there were no other significant differences in clinical characteristics between these two groups.
Time-Electrophysiologic Effect Relations
The data collected from group 1 patients demonstrated two distinct time courses of electrophysiologic changes after amiodarone therapy initiation. Changes in conduction intervals and measures of the electrophysiology of the atrium and of the sinus and AV nodes occurred within 2 weeks of amiodarone therapy without further changes thereafter (Figure 1, upper panel) . In contrast, changes in measures of ventricular repolarization and refractoriness were not completed until after 10 weeks of amiodarone therapy (Figure 1, lower panel) . There were no changes in any electrophysiologic measurement between the 10-week and the 20-week electrophysiologic studies. Based on these initial observations, group 2 patients were assessed at baseline and after 2 and 10 weeks of therapy. These data and the data from group 1 patients were combined and are presented in Table 2 .
The majority of the electrophysiologic effects of amiodarone demonstrated an "early" time course of onset with no significant change after 2 weeks of therapy (Table 2) . However, two measurements demonstrated additional significant changes after the 2-week study. The QT interval during fixed rate atrial pacing increased from baseline (355 ±36 msec)
to the 2-week study (406+37 msec) (p<0.001) and then increased further after 10 weeks of therapy Figure 2 , there was a significant decrease in VPB frequency after 2 weeks of amiodarone therapy (37±118/hr; average reduction, 77%) (p<0.01) that did not change further after 10 weeks of therapy (32±84/hr; average reduction, 80%). Of the 25 patients with a baseline VPB frequency of 10/hr or more, 18 patients (72%) had at least 80% VPB suppression after 2 weeks of therapy. In contrast, a cumulative antiarrhythmic effect as assessed by inducible ventricular tachycardia was noted between the 2-and 10-week electrophysiologic studies. All patients had inducible ventricular tachycardia before amiodarone administration and after 2 weeks of amiodarone therapy. However, three patients did not have inducible ventricular tachycardia at the time of the 10-week electrophysiologic study (p=0.07). Of the 31 remaining patients with inducible ventricular tachycardia at each of the electrophysiologic studies, 22 patients had the same ventricular tachycardia induced at each study. As shown in Figure 2 , the ventricular tachycardia cycle length increased from baseline (248±60 msec) to the 2-week study (313+69 msec) (p<0.001) and then increased further after 10 weeks of therapy (341 ±79 msec) (p<0.05).
The time course of a beneficial antiarrhythmic response to amiodarone was assessed in the 11 group After 2 weeks of amiodarone therapy, three of the 11 patients (27%) demonstrated a beneficial response; after 6 weeks of therapy, four patients (36%) had beneficial response; and after 10 weeks of therapy, six patients (55%) had a beneficial response. No further increase in the proportion of patients demonstrating a beneficial response occurred between the 10-and 20-week electrophysiologic studies.
Time-Concentration Relations
The time dependence of amiodarone and desethylamiodarone serum concentrations are shown in 1.4±0.7 1,g/ ml, respectively). However, the mean serum desethylamiodarone concentration increased from the second week (0.8±0.3 ,ug/ml) to the tenth week of therapy (1.0±0.4 ,ug/ml) (p=0.03). Relations between changes in electrophysiologic measurements and serum concentrations of amiodarone and desethylamiodarone were examined by linear regression. The data points for this linear regression analysis were defined by a change in an electrophysiologic measurement (value at time t -value at baseline) and by the serum drug concentrations at time t. Accordingly, data from group 1 patients included 2-, 6-, 10-, and 20-week samples while data from group 2 patients included 2-and 10-week samples. Changes in seven electrophysiologic measurements were significantly correlated with either amiodarone or desethylamiodarone concentrations (Table 3) . Changes in five measurements (spontaneous sinus cycle length, paced AH interval, AVERP, AVFRP, and WCL) were significantly correlated with serum amiodarone concentration. The time course of change of each of these measurements was early (completed within 2 weeks; see Figure 1 ). The change in VFRP was significantly correlated with serum desethylamiodarone concentration. The time course of change in this measurement was late (not completed until 10 weeks of therapy; see Figure 1 ). The change in VERP was significantly correlated with both serum amiodarone and desethylamiodarone concentrations. The time course of change of this measurement was intermediate between the early and late patterns (see Figure 1) . Discussion The present study assessed time courses of onset of electrophysiologic and antiarrhythmic effects of amiodarone using an oral loading dosage regimen representative of those in general use. Most of the electrophysiologic effects of amiodarone have reached steady state 2 weeks after therapy initiation. These early effects are those of Class I (sodium channel blocking), Class IV (calcium channel blocking), and antiadrenergic activities. In contrast, the effects of amiodarone on QT interval and on VERP and VFRP are not maximal for 6-10 weeks. These late effects have a common dependence on prolongation of ventricular muscle action potential duration. Onset of the ventricular antiarrhythmic effects of amiodarone also follows two different time courses. Suppression of VPB frequency is maximal within 2 weeks. However, effects on inducibility of ventricular tachycardia and on the cycle length of ventricular tachycardia are not maximal for 10 weeks. Early effects tend to correlate with serum amiodarone concentrations, whereas late effects tend to correlate with serum desethylamiodarone concentrations.
Time-Electrophysiologic Effect Relations
The 
Conclusions
The present study demonstrates that the time courses of onset of the electrophysiologic and antiarrhythmic effects of amiodarone vary depending on the site and type of effect. Those effects with the latest course of onset include changes in ventricular effective and functional refractory periods, QT interval, ventricular tachycardia inducibility, and ventricular tachycardia cycle length. These changes require 10 weeks of therapy to become maximal despite the use of oral loading dosage regimens.
